Global Retinal Biologics Market Is Expected To Reach Around USD 28,015 Million By 2025

16-Sep-2019 | Zion Market Research

Zion Market Research has published a new report titled “Retinal Biologics Market By Drug Class (TNF-a Inhibitor and VEGF-A Antagonist), By Indication (Diabetic Retinopathy, Macular Degeneration, Uveitis, Diabetic Macular Edema, and Others), and by Distribution Channel (Retail Sales and Institutional Sales): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global retinal biologics market was USD 13,082 million in 2018 and is expected to generate around USD 28,015 million by 2025, at a CAGR of 11.5% between 2019 and 2025.

The retina is a sensitive and delicate part of the human eye, which receives and processes light and converts it into neural signals and forwards them to the brain for performing visual activities. Retinal disorders include macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis.

Global Retinal Biologics Market

Browse the full “Retinal Biologics Market By Drug Class (TNF-a Inhibitor and VEGF-A Antagonist), By Indication (Diabetic Retinopathy, Macular Degeneration, Uveitis, Diabetic Macular Edema, and Others), and by Distribution Channel (Retail Sales and Institutional Sales): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at

The worldwide escalation of ophthalmic disorders, due to aging, is the prime factor driving the retinal biologics market globally. The development of several new products in the form of drug-releasing implants and biologics due to the consistent efforts for developing better treatment options are further propelling the market for retinal biologics. However, the limited availability of the biologics, adverse effects of biologics, and strict regulatory requirements associated with biologics approval may hamper the market for retinal biologics in the future.

The retinal biologics market is fragmented based on drug class, indication, and distribution channel. By drug class, the market includes TNF-α inhibitor and VEGF-An antagonist. The TNF-α inhibitor is expected to register a higher CAGR in the retinal biologics market over the forecast time period. The VEGF-A antagonist accounted for the largest share in the global market in 2018, as VEGF-A antagonist is widely available in the market for treating retinal disorders.

On the basis of indication, the retinal biologics market comprises diabetic macular edema, macular degeneration, diabetic retinopathy, uveitis, and others. The macular degeneration accounted for the largest share in the retinal biologic market in 2018, as macular degeneration (MD), is among the major causes of vision loss. Diabetic macular edema and diabetic retinopathy accounted for significant shares in the global market. Growing incidences of diabetes complications and the rising diabetes epidemic will continue to boost the growth of these segments.

The distribution channel segment includes retail sales and institutional sales. The retail sales segment includes mail order and retail pharmacies. The institutional sales segment is bifurcated into specialty clinics and hospitals. The institutional sales segment accounted for the largest share in the retinal biologics market in 2018. In institutional sales, the specialty clinics accounted for the larger market share.

In Europe, rising incidences retinal disorders is fuelling the regional retinal biologics demand. This, in turn, is supporting the region’s retinal biologics market. The cases of retinal diseases in the Asia Pacific region were less as compared to other regions. However, this figure is likely to increase in the upcoming years, which will support the region’s retinal biologics market. Diabetes plays a significant role in retinal disease treatment. The rising rate of diabetes in the developing nations, due to unhealthy habits and inactive lifestyle, will also boost the retinal biologics market in the region.

Some key players of the retinal biologics market are Janssen Biotech, Alimera Sciences, F. Hoffmann-La Roche, Ocular Therapeutix, Genzyme Corporation, UCBCares, AbbVie, Allergan, Swedish Orphan Biovitrum, Genentech, Bristol-Myers Squibb, and Bausch & Lomb.

This report segments the global retinal biologics market into:

Global Retinal Biologics Market: Drug Class Analysis

  • TNF-α Inhibitor
  • VEGF-A Antagonist

Global Retinal Biologics Market: Indication Analysis

  • Diabetic Retinopathy
  • Macular Degeneration
  • Uveitis
  • Diabetic Macular Edema
  • Others

Global Retinal Biologics Market: Distribution Channel Analysis

  • Retail Sales
    • Mail Order Pharmacies
    • Retail Pharmacies
  • Institutional Sales
    • Hospitals
    • Specialty Clinics

Global Retinal Biologics Market: Regional Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed